Changing the diagnostic paradigm by empowering patient consumers to chart the future of their healthcare with real time, at home and accurate diagnostic testing. Q & I Diagnostics technology removes market dependency on subscription based platforms and centralized testing facilities to ensure cost effective real time diagnosis and an immediate path to treatment. In other words you can test yourself and obtain information about your status- at home. Q & I Diagnostics is focused on developing innovative In Vitro Diagnostic (IVD) devices with integrated technology at the point of use connecting the patient consumer with their health care practitioner to allow for real time diagnosis of Covid 19 and an ever increasing incidence of viral mediated diseases.
Our Point of Care (POC) products:
- Most EXPANSIVE Assays covering ENTIRE DISEASE LIFECYCLE
- Technology Conceived and Conceptualized for SARS-CoV-2
- Extendable to many other diseases equally- TB, Hep C, cancer
- Total of 4 pending patents – 2 for platform tech and 1 each for the assays
- User-friendly APP for tracking DISEASE SPREADING and for REAL TIME CONTACT TRACING
- Serology- 15 min to answer.
- Genetic test- 35 min to answer.
- Easy to use disposable consumables.
- Simplified process
- Lower cost per test
- Convenience
- Removes unsafe testing site
Business Model:
Covid-19 Market size: US 2020 $1.5 Billion, World 2020 $3.4 Billion;
POC Market size: US 2026 $50.6 Billion with CAGR ~10%.
Gross profit margin ~60%.
Competitive price point. Inexpensive technology. Recurring consumables.
Market expansion of at-home diagnostic testing. B2C via website, B2B via retail clinics, GPs.
Projected Revenue:
Y1- Q2 $100M, Q3 $220M, Q4 $750M;
Y2- Q1 $557M, Q2 $245M, Q3 $246M, Q4 $246M;
Y3- Q1 $128M, Q2 $128M, Q3 $136M, Q4-$136M
Team:
- Dr Gerson R Aguirre, PhD, Q&I, LLC- CEO- Co-Founder.
10+ years experience in managing and developing R&D technologies for POC and molecular diagnostics.
Holds 7 patents in POC tech.
Consultant providing solutions for IVD product development.
Director of Microfluidics, Zepto Life Technologies.
Lead Mech Eng, Stratos Genomics (acquisition by Roche).
- Dr Chandra Dixit, PhD, Q&I, LLC- COO- Co-Founder.
15+ years of experience developing tools and methods for bioanalytical and IVD applications at GLP/cGMP.
Holds 3 patents in IVD .
Scientific Expert, QIAGEN (acquisition by Thermo)
Senior Scientist, PBL Assay Science
Transferred over 7 technologies to industry
Published over 40 high impact journal articles and one book.
INITIAL ROUND HISTORY
•. Financing History: Founders $182.51k
•. Secured IP (4 patents) for technology
•. Milestones for first 12 months: 1) Launch Serology test within 4 months and Genetic test in 7 months under EUA, 2) Clinical validation for regular FDA 510K submission
•. Submitted SBIR I application
•. Exit Strategy: Licensing, IPO
Ready to Ask For Funding for your company?
Post a Funding Request